ISO 17025 Third-Party COA Verification • Consumer Label Accuracy Report

Clinical Head-to-Head 2026 Lab Audit: Pass/Fail Purity, Gummy Under-Dosing & Heavy Metal Screening

Independent 2026 laboratory audit of Clinical Head-to-Head supplements: ISO 17025 Certificate of Analysis (COA) verification, Prop 65 heavy metal screening, and cost-per-effective-gram rankings.

Why Commercial Clinical Head-to-Head Formulations Fail Independent Testing

  • Gummy & Liquid Degradation Risk: Heat-processed pectin gummies and unbuffered liquid suspensions frequently exhibit 40%–85% active compound degradation prior to shelf expiration.
  • Heavy Metal & Prop 65 Thresholds: Raw botanical and mineral extracts must be batch-screened via ICP-MS for Lead (<0.5 mcg/serving), Arsenic, Cadmium, and Mercury.
  • Bioavailable Clinical Benchmark: Verify standardized extract potency matching human RCT dosing (Semaglutide: 2.4mg weekly | Tirzepatide: 10mg - 15mg weekly).
View Verified Clinical Head-to-Head Brands & COA Table → Calculate Clinical Head-to-Head mg/kg Dosage → Check Clinical Head-to-Head Drug Contraindications →